Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2017

Open Access 01-02-2017 | Review Article

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

Authors: Bernd Tischer, Renate Huber, Matthias Kraemer, Mario E. Lacouture

Published in: Supportive Care in Cancer | Issue 2/2017

Login to get access

Abstract

Purpose

As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety of dermatologic adverse events (dAEs), the purpose of this study was to develop an overview of current knowledge of dAEs associated with EGFR inhibitors and to identify knowledge gaps regarding incidence, treatment, impact on quality of life (QOL), and patient acceptance.

Method

A structured literature search was conducted using MEDLINE/PubMed (January 1983 to January 2014). In total, 71 publications published from 2004 to 2014 were identified for consideration in the final evidence review.

Results

The majority of published articles concentrate on the incidence of skin reactions, duration, treatment, and prevention strategies. Different grading systems based on the symptoms of skin rash or on health-related QOL (HRQOL) are used. An additional topic is the possible correlation between acneiform rash and efficacy of EGFR inhibitors. Knowledge gaps identified in the literature were how dAEs impact QOL compared with other AEs from a patient’s perspective, patients’ acceptance of dAEs (willingness to tolerate), and the impact of physician-patient communication on treatment decisions.

Conclusions

Research is needed on the impact of dAEs on patients’ acceptance of cancer treatments. Systematic studies are missing that compare the impact of dAEs with other toxicities on therapy decisions from both physician’s and patient’s view, and that investigate the balance between efficacy and avoidance of acneiform rash in treatment decisions. Such studies could provide deeper insights into the acceptance of the risk of untoward dermatologic events by both physicians and patients when treating advanced cancers.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Balagula Y, Lacouture ME, Cotliar JA (2010) Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8:149–161CrossRefPubMed
4.
Tan EH, Chan A (2009) Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 43:1658–1666CrossRefPubMed
5.
Lacouture ME (2014) Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair and Nails in Cancer Patients. John Wiley & Sons, Hoboken
6.
Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A (2011) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524–535CrossRefPubMed
7.
Burish TG, Snyder SL, Jenkins RA (1991) Preparing patients for cancer chemotherapy: effect of coping preparation and relaxation interventions. J Consult Clin Psychol 59:518–525CrossRefPubMed
8.
Ensslin CJ, Rosen AC, Wu S, Lacouture ME (2013) Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69:708–720CrossRefPubMedPubMedCentral
9.
Frith H, Harcourt D, Fussell A (2007) Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs 11:385–391CrossRefPubMed
10.
Krueger C (2010) Management of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatologic Toxicity
11.
Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O’Brien D, Hauschild A (2013) Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 13:721–728CrossRefPubMed
12.
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357CrossRefPubMed
13.
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–3015CrossRefPubMed
14.
Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433CrossRefPubMed
15.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095CrossRefPubMedPubMedCentral
16.
Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME (2015) A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer 23:2231–2244CrossRefPubMedPubMedCentral
17.
Jia Y, Lacouture ME, Su X, Wu S (2009) Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 7:211–217PubMed
18.
Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME (2012) Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 67:1025–1039CrossRefPubMed
19.
20.
Abdullah SE, Haigentz M Jr, Piperdi B (2012) Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract 2012:351210PubMedPubMedCentral
21.
McGarvey EL, Baum LD, Pinkerton RC, Rogers LM (2001) Psychological sequelae and alopecia among women with cancer. Cancer Pract 9:283–289CrossRefPubMed
22.
Williams SA, Schreier AM (2004) The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 31:E16–E23CrossRefPubMed
23.
Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9:59–60CrossRefPubMed
24.
Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980–988CrossRefPubMed
25.
Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147. Oncology 77:120–123
26.
Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL, North Central Cancer Treatment Group (2011) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 19:1601–1607CrossRefPubMed
27.
Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL (2010) Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 15:1016–1022CrossRefPubMedPubMedCentral
28.
Li J, Peccerillo J, Kaley K, Saif MW (2009) Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 10:338–340PubMed
29.
Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208CrossRefPubMed
30.
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159CrossRefPubMed
31.
Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89–96CrossRefPubMed
32.
Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG Jr, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E (2013) Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 31:4504–4511CrossRefPubMed
33.
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577CrossRefPubMed
34.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefPubMed
35.
Colagiuri B, Dhillon H, Butow PN, Jansen J, Cox K, Jacquet J (2013) Does assessing patients’ expectancies about chemotherapy side effects influence their occurrence? J Pain Symptom Manage 46:275–281CrossRefPubMed
36.
Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C (2010) Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 78:249–258CrossRefPubMed
37.
Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414–6421CrossRefPubMed
38.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMed
39.
Leporini C, Saullo F, Filippelli G, Sorrentino A, Lucia M, Perri G, Gattuta GL, Infusino S, Toscano R, Dima G, Olivito V, Paletta L, Bottoni U, De Sarro G (2013) Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: a case review. J Pharmacol Pharmacother 4:S78–S85PubMedPubMedCentral
40.
Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK (2011) Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 105:938–944CrossRefPubMedPubMedCentral
41.
Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP (2005) Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 16:780–785CrossRefPubMed
42.
Palmer NR, Kent EE, Forsythe LP, Arora NK, Rowland JH, Aziz NM, Blanch-Hartigan D, Oakley-Girvan I, Hamilton AS, Weaver KE (2014) Racial and ethnic disparities in patient-provider communication, quality-of-care ratings, and patient activation among long-term cancer survivors. J Clin Oncol 32:4087–4094CrossRefPubMedPubMedCentral
43.
Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 22:3238–3247CrossRefPubMed
44.
Pircher A, Ulsperger E, Hack R, Jamnig H, Pall G, Zelger B, Sterlacci W, Hilbe W, Fiegl M (2011) Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. Anticancer Res 31:2949–2955PubMed
45.
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85CrossRefPubMed
46.
Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S (2013) Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. Springerplus 2:22-1801-2-22. Epub 2013 Jan 23
47.
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Banos A, Kohne CH (2012) Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12:438-2407-12-438
48.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMed
49.
Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30:2861–2868
50.
Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792–797CrossRefPubMedPubMedCentral
51.
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921CrossRefPubMed
52.
West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR (2006) Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24:1807–1813CrossRefPubMed
53.
Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2010) Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes 8:40-7525-8-40
54.
Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA (2013) Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. Eur J Oncol Nurs 17:802–807CrossRefPubMed
55.
Munhoz BA, Paiva HS, Abdalla BM, Zaremba G, Rodrigues AM, Carretti MR, Monteiro CR, Zara A, Silva JO, Assis WB, Auresco LC, Pereira LL, Giglio AB, Lepori AC, Trufelli DC, del Giglio A (2014) From one side to the other: what is essential? Perception of oncology patients and their caregivers in the beginning of oncology treatment and in palliative care. Einstein (Sao Paulo) 12:485–491CrossRef
56.
Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161:515–521CrossRefPubMed
57.
Romito F, Giuliani F, Cormio C, Tulipani C, Mattioli V, Colucci G (2010) Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 18:329–334CrossRefPubMed
58.
Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327–333CrossRefPubMed
59.
Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469–1478CrossRefPubMedPubMedCentral
60.
Unger K, Niehammer U, Hahn A, Goerdt S, Schumann M, Thum S, Schepp W (2013) Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. Z Gastroenterol 51:733–739CrossRefPubMed
61.
Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21:1033–1041CrossRefPubMed
62.
Chren MM (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30:231–6, xiii
63.
64.
Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21:34–36
65.
Binder D, Buckendahl AC, Hubner RH, Schlattmann P, Temmesfeld-Wollbruck B, Beinert T, Suttorp N (2012) Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol 29:193–198CrossRefPubMed
66.
Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 5:1616–1622CrossRefPubMed
67.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMed
68.
Tiseo M, Gridelli C, Cascinu S, Crino L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A (2009) An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer 64:199–206CrossRefPubMed
69.
Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB (2010) Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 5:1048–1053CrossRefPubMedPubMedCentral
70.
Borsellino M, Young MM (2011) Anticipatory coping: taking control of hair loss. Clin J Oncol Nurs 15:311–315CrossRefPubMed
71.
Waters EA, Weinstein ND, Colditz GA, Emmons K (2009) Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol 28:201–209CrossRefPubMedPubMedCentral
72.
Girones R (2015) Desire for information in the elderly: interactions with patients, family, and physicians. J Cancer Educ 30:766–773CrossRefPubMed
73.
Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812CrossRefPubMed
74.
Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE (2010) A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 16:1915–1923CrossRefPubMed
Metadata
Title
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
Authors
Bernd Tischer
Renate Huber
Matthias Kraemer
Mario E. Lacouture
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3419-4

Other articles of this Issue 2/2017

Supportive Care in Cancer 2/2017 Go to the issue

Original Article

Lost and stranded: the experience of younger adults with advanced cancer

Original Article

A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

Original Article

Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications

Original Article

Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials

Letter to the editor

Response to letter to the Editors—Safety of long-term denosumab therapy

Original Article

Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits